Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Biliary tract cancers (BTCs) account for <1% of all human cancers. Cholangiocarcinoma (CCA) is the second most common primary liver cancer after hepatocellular carcinoma (HCC), accounting for ∼10%-15% of all primary liver cancers.1 The global mortality rate for CCA has increased worldwide during recent decades according to World Health Organization and Pan American Health Organization databases for 32 selected locations in Europe, America, Asia and Oceania. …
Continua a leggere

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma

Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibitor, has been shown to have both antitumor activity in patients with FGFR-altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors. …
Continua a leggere

Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial

S-1 has shown promising efficacy with a mild toxicity profile in patients with advanced biliary tract cancer. The aim of this study was to evaluate whether adjuvant S-1 improved overall survival compared with observation for resected biliary tract cancer. This open-label, multicentre, randomised phase 3 trial was conducted in 38 Japanese hospitals. Patients aged 20-80 years who had histologically confirmed extrahepatic …
Continua a leggere

Cholangiocarcinoma: what are the options in all comers and how has the advent of molecular profiling opened the way to personalised medicine ?

Cholangiocarcinoma is a deadly cancer comprising very heterogenous subtypes with a limited therapeutic arsenal in all comers. However, recent significant advances were made with immunotherapy in the first-line treatment of advanced cholangiocarcinoma, with the addition of durvalumab to cisplatin-gemcitabine chemotherapy showing a survival benefit. In the second line setting, only FOLFOX (5FU/folinic acid-oxaliplatin) is validated by a phase 3 trial, yet with a very …
Continua a leggere

2023 News in Oncology from USA to Italy
Bologna / FAD sincrona, 22 – 23 giugno 2023

5° Corso IEO sui tumori neuroendocrini funzionanti
Assago (MI), 26 giugno 2023

Gourmeet
Roma, 27 giugno 2023

44th International Conference on Screening for Lung Cancer
Verona, 28 – 30 giugno 2023

From Chicago to Pesaro&Urbino: update in oncologia
Urbino, 30 giugno 2023

Stato dell’arte dell’immunonutrizione nel paziente oncologico
FAD, 30 giugno 2023 – 30 aprile 2024

Supportive care & quality of life
Padova, 30 giugno – 1° luglio 2023

New perspectives of clinical research in gynecological cancer
Pisa, 30 giugno – 1° luglio 2023

Tumore della mammella: Il punto di vista della Donna
Bari, 30 giugno – 1 luglio 2023

AIOM Giovani Calabria: dalla ricerca traslazionale alla target therapy e all’immunoterapia
Catanzaro, 1 luglio 2023

Landscapes in Oncologia 2023
Milano, 3 – 4 luglio 2023

Gestione multidisciplinare del paziente oncologico con endocrinopatie: Webinar AIOM-AMD-SID-SIE-SIF
I mercoledì dell’oncologia
Webinar, 5 luglio 2023 dalle 17.00 alle 18.15

We BRCA Breast
Webinar, 5 luglio 2023

Congresso Mesotelioma- Let’s network
Milano, 7 Luglio 2023

Convegno Nazionale AIOM Giovani Oncologi
Perugia, 7 – 8 luglio 2023

Neoplasie del colon retto
Roma, 11 luglio 2023

Nuove frontiere e algoritmi di trattamento nel colangiocarcinoma
I mercoledì dell’oncologia
Webinar ECM, 12 luglio 2023 dalle 17.00 alle 18.15

Tumore alla prostata e raccomandazioni del Consiglio dell’Unione Europea
Webinar 13 luglio 2023 

XXV Congresso Nazionale AIOM
Roma, 10 – 12 novembre 2023